Increased Susceptibility to Methotrexate-Induced Toxicity in Nonalcoholic Steatohepatitis

Anstee, 2011, Genetic modifiers of non-alcoholic fatty liver disease progression, Biochim. Biophys. Acta, 1812, 1557, 10.1016/j.bbadis.2011.07.017

Barker, 2011, Assessment and management of methotrexate hepatotoxicity in psoriasis patients: Report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic, J. Eur. Acad. Dermatol. Venereol., 25, 758, 10.1111/j.1468-3083.2010.03932.x

Butturini, 2007, Obesity and outcome in pediatric acute lymphoblastic leukemia, J. Clin. Oncol., 25, 2063, 10.1200/JCO.2006.07.7792

Chen, 2002, Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system, Cancer Res., 62, 3144

Cheung, 2009, Recent advances in nonalcoholic fatty liver disease, Curr. Opin. Gastroenterol., 25, 230, 10.1097/MOG.0b013e3283294a18

Cole, 2000, High-dose methotrexate is lethal to rats. Why give it to children, Pediatr. Hematol. Oncol., 17, 609, 10.1080/08880010050211312

Fisher, 2009, Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats, Eur. J. Pharmacol., 613, 119, 10.1016/j.ejphar.2009.04.002

Fisher, 2009, Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease, Drug Metab. Dispos., 37, 2087, 10.1124/dmd.109.027466

Guo, 2007, Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry, J. Pharm. Biomed. Anal., 43, 1789, 10.1016/j.jpba.2006.12.034

Hardwick, 2013, Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease, Drug Metab. Dispos., 41, 554, 10.1124/dmd.112.048439

Hardwick, 2010, Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease, Drug Metab. Dispos., 38, 2293, 10.1124/dmd.110.035006

Hardwick, 2011, Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease, Drug Metab. Dispos., 39, 2395, 10.1124/dmd.111.041012

Hardwick, 2012, Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis, Drug Metab. Dispos., 40, 450, 10.1124/dmd.111.041095

Kato, 2009, Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate, Pharm. Res., 26, 1467, 10.1007/s11095-009-9858-6

Kitamura, 2008, Increasing systemic exposure of methotrexate by active efflux mediated by multidrug resistance-associated protein 3 (mrp3/abcc3), J. Pharmacol. Exp. Ther., 327, 465, 10.1124/jpet.108.140475

Lake, 2011, Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease, Drug Metab. Dispos., 39, 1954, 10.1124/dmd.111.040592

Langman, 2001, Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury, J. Gastroenterol. Hepatol., 16, 1395, 10.1046/j.1440-1746.2001.02644.x

Lickteig, 2007, Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease, Drug Metab. Dispos., 35, 1970, 10.1124/dmd.107.015107

Marra, 2008, Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis, Trends Mol. Med., 14, 72, 10.1016/j.molmed.2007.12.003

McCullough, 2011, Epidemiology of the metabolic syndrome in the USA, J. Dig. Dis., 12, 333, 10.1111/j.1751-2980.2010.00469.x

Mencin, 2011, Advances in pediatric nonalcoholic fatty liver disease, Pediatr. Clin. North Am., 58, 1375, 10.1016/j.pcl.2011.09.005

Schmiegelow, 2009, Advances in individual prediction of methotrexate toxicity: A review, Br. J. Haematol., 146, 489, 10.1111/j.1365-2141.2009.07765.x

Shibayama, 2006, Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats, Cancer Sci., 97, 1260, 10.1111/j.1349-7006.2006.00304.x

Smeland, 1994, Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat, Cancer Chemother. Pharmacol., 34, 119, 10.1007/BF00685928

USFDA, 2012, Adverse Events Reporting System Statistics. Patient Outcomes by Year

Vlaming, 2009, Functionally overlapping roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate in vivo, Clin. Cancer Res., 15, 3084, 10.1158/1078-0432.CCR-08-2940

Vlaming, 2008, Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate, Clin. Cancer Res., 14, 8152, 10.1158/1078-0432.CCR-08-1609

Vlaming, 2009, Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo, Mol. Cancer Ther., 8, 3350, 10.1158/1535-7163.MCT-09-0668

Vlaming, 2011, Impact of abcc2 [multidrug resistance-associated protein (MRP) 2], abcc3 (MRP3), and abcg2 (breast cancer resistance protein) on the oral pharmacokinetics of methotrexate and its main metabolite 7-hydroxymethotrexate, Drug Metab. Dispos., 39, 1338, 10.1124/dmd.111.038794

Wang, 2011, Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models, Drug Metab. Dispos., 39, 2155, 10.1124/dmd.111.041228

Warren, 2008, Systemic therapies for psoriasis: Methotrexate, retinoids, and cyclosporine, Clin. Dermatol., 26, 438, 10.1016/j.clindermatol.2007.11.006

Widemann, 2006, Understanding and managing methotrexate nephrotoxicity, Oncologist, 11, 694, 10.1634/theoncologist.11-6-694

Wilke, 2007, Identifying genetic risk factors for serious adverse drug reactions: Current progress and challenges, Nat. Rev. Drug Discov., 6, 904, 10.1038/nrd2423